Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination With PD-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients After Failure of Frontline Therapy (ACTION)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; TT 11 (Primary) ; Bendamustine; Fludarabine
Indications Hodgkin's disease
Focus Adverse reactions
Acronyms ACTION
Sponsors Tessa Therapeutics

Most Recent Events

16 Jun 2023 Results presented in the Tessa Therapeutics Media Release.
15 Jun 2023 Results presented in the Tessa Therapeutics Media Release.
15 Jun 2023 According to a Tessa Therapeutics media release, data from this study were presented at the17th International Conference on Malignant Lymphoma.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight